Orthofix International N.v Stock News

Orthofix Medical Inc. (NASDAQ:OFIX) Director Catherine M. Burzik acquired 1,660 shares of the stock in a transaction that occurred on Friday, November 19th. The shares were bought at an average price of $30.27 per share, for a total transaction of $50,248.20. The acquisition was disclosed in a document filed with the SEC, which is available []

Orthofix Medical (NASDAQ:OFIX) updated its FY 2021 earnings guidance on Friday. The company provided EPS guidance of $0.710-$0.750 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.730. The company issued revenue guidance of $460 million-$464 million, compared to the consensus revenue estimate of $467.43 million. Separately, Zacks Investment Research cut Orthofix []

Related Stocks: OFIX ,

Analysts expect that Orthofix Medical Inc. (NASDAQ:OFIX) will report earnings per share of $0.12 for the current quarter, according to Zacks. Two analysts have made estimates for Orthofix Medicals earnings, with the highest EPS estimate coming in at $0.13 and the lowest estimate coming in at $0.11. Orthofix Medical posted earnings per share of $0.44 []

Brokerages expect that Orthofix Medical Inc. (NASDAQ:OFIX) will report $0.12 earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have made estimates for Orthofix Medicals earnings. The lowest EPS estimate is $0.11 and the highest is $0.13. Orthofix Medical reported earnings per share of $0.44 in the same quarter last year, which []

Orthofix Medical Inc. (OFIX) CEO Jon Serbousek on Q3 2021 Results - Earnings Call Transcript

Backed by robust long-term prospects, investors can add three lucrative MedTech stocks, MMSI, ITGR and OFIX, to their watchlist.

OrthoPediatrics (KIDS), Orthofix (OFIX), Zimmer Biomet (ZBH), Stryker (SYK) and SeaSpine (SPNE) are expected to hold ground despite a challenging business climate.

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that President and Chief Executive Officer

Orthofix's (OFIX) Fitbone system is the only intramedullary limb lengthening solution to get FDA clearance for pediatric and adult use.

Orthofix Medical's (OFIX) CEO Jon Serbousek on Q2 2021 Results - Earnings Call Transcript

Orthofix Medical Inc (NASDAQ: OFIX) reported Q2 adjusted EPS $0.32, compared to an adjusted net loss of $(0.59) a year ago, beating the consensus of $0.11. Sales increased 66% to $121.4 million.

Orthofix (OFIX) delivered earnings and revenue surprises of 100.00% and 11.01%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended June 30, 2021. Net sales were $121 million, earnings per share (“EP

Orthofix's (OFIX) SpinalStim bone growth device demonstrates impressive fusion rates for patients recovering from lumbar fusion surgery.